nach oben

European Radiology

Erschienen in:

05.04.2023 | Gastrointestinal

LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium–enhanced magnetic resonance imaging

verfasst von: Hyeon Ji Jang, Sang Hyun Choi, Se Jin Choi, Won-Mook Choi, Jae Ho Byun, Hyung Jin Won, Yong Moon Shin

Erschienen in: European Radiology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Objectives

We aimed to develop and evaluate a modified Liver Imaging Reporting and Data System (LI-RADS) version 2018 using significant ancillary features for diagnosing hepatocellular carcinoma (HCC) < 1.0 cm on gadoxetate disodium–enhanced magnetic resonance imaging (MRI).

Methods

Patients who underwent preoperative gadoxetate disodium–enhanced MRI for focal solid nodules < 2.0 cm within 1 month of MRI between January 2016 and December 2020 were retrospectively analyzed. Major and ancillary features were compared between HCCs of < 1.0 cm and 1.0–1.9 cm using the chi-square test. Significant ancillary features associated with HCC < 1.0 cm were determined by univariable and multivariable logistic regression analysis. The sensitivity and specificity of LR-5 were compared between LI-RADS v2018 and our modified LI-RADS (applying the significant ancillary feature) using generalized estimating equations.

Results

Of 796 included nodules, 248 were < 1.0 cm and 548 were 1.0–1.9 cm. HCC < 1.0 cm less frequently showed an enhancing capsule (7.1% vs. 31.1%, p < .001) and threshold growth (0% vs. 8.3%, p = .007) than HCC of 1.0−1.9 cm. Restricted diffusion was the only ancillary feature significant for diagnosing HCC < 1.0 cm (adjusted odds ratio = 11.50, p < .001). In the diagnosis of HCC, our modified LI-RADS using restricted diffusion had significantly higher sensitivity than LI-RADS v2018 (61.8% vs. 53.5%, p < .001), with similar specificity (97.3% vs. 97.8%, p = .157).

Conclusion

Restricted diffusion was the only significant independent ancillary feature for diagnosing HCC < 1.0 cm. Our modified LI-RADS using restricted diffusion can improve the sensitivity for HCC < 1.0 cm.

Key Points

• The imaging features of hepatocellular carcinoma (HCC) < 1.0 cm differed from those of HCC of 1.0–1.9 cm.

• Restricted diffusion was the only significant independent ancillary feature for HCC < 1.0 cm.

• Modified Liver Imaging Reporting and Data System (LI-RADS) with the addition of restricted diffusion can improve the sensitivity for HCC < 1.0 cm.

Nur mit Berechtigung zugänglich

McGlynn KA, Petrick JL, El-Serag HB (2021) Epidemiology of hepatocellular carcinoma. Hepatology 73(Suppl 1):4–13CrossRefPubMed

Llovet JM, Fuster J, Bruix J (2004) The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10:S115-120CrossRefPubMed

Hasegawa K, Kokudo N, Makuuchi M et al (2013) Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 58:724–729CrossRefPubMed

Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRefPubMed

European Association for the Study of the Liver (2018) EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236

Fan PL, Chu J, Wang Q, Wang C (2022) The clinical value of dual-energy computed tomography and diffusion-weighted imaging in the context of liver cancer: a narrative review. J Clin Ultrasound 50:862–868CrossRefPubMed

Joo I, Lee JM (2016) Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI. Liver Cancer 5:67–87CrossRefPubMed

Ichikawa T, Saito K, Yoshioka N et al (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45:133–141CrossRefPubMed

Choi SH, Byun JH, Lim YS et al (2016) Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 64:1099–1107CrossRefPubMed

10.

Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370CrossRefPubMed

11.

Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y (2014) Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. Oncology 87(Suppl 1):7–21CrossRefPubMed

12.

Lee S, Kim SS, Chang DR, Kim H, Kim MJ (2020) Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 26:340–351CrossRefPubMedPubMedCentral

13.

Kim DH, Choi SH, Byun JH et al (2019) Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 71:534–542CrossRefPubMed

14.

Park CJ, An C, Park S, Choi JY, Kim MJ (2018) Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC. Eur Radiol 28:1476–1484CrossRefPubMed

15.

GuPta PP, Lohiya N (2022) Radiological outcome of subcentimeter arterially enhancing nodules detected during surveillance for hepatocellular carcinoma-a cohort study. J Clin Diagn Res 16:TC01-TC05

16.

Song KD, Lee MW, Rhim H et al (2018) Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes. Radiology 288:878–886CrossRefPubMed

17.

Kim BJ, Choi SH, Kim SY et al (2022) Liver Imaging Reporting and Data System categories: long-term imaging outcomes in a prospective surveillance cohort. Liver Int 42:1648–1657CrossRefPubMed

18.

Yu MH, Kim JH, Yoon JH et al (2014) Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology 271:748–760CrossRefPubMed

19.

Campos-Correia D, Cruz J, Matos AP, Figueiredo F, Ramalho M (2018) Magnetic resonance imaging ancillary features used in Liver Imaging Reporting and Data System: an illustrative review. World J Radiol 10:9–23CrossRefPubMedPubMedCentral

20.

Park JH, Chung YE, Seo N, Choi JY, Park MS, Kim MJ (2021) Should threshold growth be considered a major feature in the diagnosis of hepatocellular carcinoma using LI-RADS? Korean J Radiol 22:1628–1639CrossRefPubMedPubMedCentral

21.

Cerny M, Chernyak V, Olivié D et al (2018) LI-RADS version 2018 ancillary features at MRI. Radiographics 38:1973–2001CrossRefPubMed

22.

Chernyak V, Fowler KJ, Heiken JP, Sirlin CB (2019) Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS). J Magn Reson Imaging 49:1236–1252CrossRefPubMed

23.

Kang JH, Choi SH, Byun JH et al (2020) Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging. Eur Radiol 30:2881–2889CrossRefPubMed

24.

Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261:834–844CrossRefPubMed

25.

Zhang Y, Liu M, Zhang Q et al (2020) MRI in the differential diagnosis between well-differentiated hepatocellular carcinomas and high-grade dysplastic nodules in cirrhotic liver. Radiol Infect Dis 7:22–27CrossRef

26.

Renzulli M, Biselli M, Brocchi S et al (2018) New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 67:1674–1682CrossRefPubMed

27.

Park MJ, Kim YK, Lee MW et al (2012) Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 264:761–770CrossRefPubMed

28.

Hwang J, Kim YK, Kim JM, Lee WJ, Choi D, Hong SS (2014) Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transpl 20:1436–1446PubMed

29.

Xie S, Zhang Y, Chen J et al (2022) Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10–19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Abdom Radiol (NY) 47:596–607CrossRefPubMed

30.

Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH (2019) Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases. Radiology 291:651–657CrossRefPubMed

31.

Jang JK, Choi SH, Byun JH et al (2022) New strategy for Liver Imaging Reporting and Data System category M to improve diagnostic performance of MRI for hepatocellular carcinoma ≤ 3.0 cm. Abdom Radiol (NY) 47:2289–2298CrossRefPubMed

32.

Rong D, He B, Tang W et al (2022) Comparison of gadobenate-enhanced MRI and gadoxetate-enhanced MRI for hepatocellular carcinoma detection using LI-RADS version 2018: a prospective intraindividual randomized study. AJR Am J Roentgenol 218:687–698CrossRefPubMed

33.

Song JS, Choi EJ, Hwang SB, Hwang HP, Choi H (2019) LI-RADS v2014 categorization of hepatocellular carcinoma: intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Eur Radiol 29:401–410CrossRefPubMed

34.

Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR (2018) Comparison of visualization rates of LI-RADS version 2014 major features with IV gadobenate dimeglumine or gadoxetate disodium in patients at risk for hepatocellular carcinoma. AJR Am J Roentgenol 210:1266–1272CrossRefPubMed

35.

Paisant A, Vilgrain V, Riou J et al (2020) Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. J Hepatol 72:937–945CrossRefPubMed

36.

Kim DW, Choi SH, Kim SY et al (2020) Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis. Hepatol Int 14(6):1009–1022

Titel: LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium–enhanced magnetic resonance imaging
verfasst von: Hyeon Ji Jang
Sang Hyun Choi
Se Jin Choi
Won-Mook Choi
Jae Ho Byun
Hyung Jin Won
Yong Moon Shin
Publikationsdatum: 05.04.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 8/2023
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-023-09554-8

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium–enhanced magnetic resonance imaging